SEC Comment Letter 0000000000-24-011398 to Seres Therapeutics, Inc. (MCRB) (CIK 0001609809) (MCRB)
Seres Therapeutics, Inc. (MCRB) (CIK 0001609809)
Date: Oct. 8, 2024 · CIK: 0001609809 · Accession: 0000000000-24-011398
AI Filing Summary & Sentiment
File numbers found in text: 333-282450
Letter
October 8, 2024 Eric Shaff Chief Executive Officer Seres Therapeutics, Inc. 101 Cambridgepark Drive Cambridge, MA 02140 Re:Seres Therapeutics, Inc. Registration Statement on Form S-3 Filed October 1, 2024 File No. 333-282450 Dear Eric Shaff: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Wesley C. Holmes, Esq.
Show Raw Text
October 8, 2024
Eric Shaff
Chief Executive Officer
Seres Therapeutics, Inc.
101 Cambridgepark Drive
Cambridge, MA 02140
Re:Seres Therapeutics, Inc.
Registration Statement on Form S-3
Filed October 1, 2024
File No. 333-282450
Dear Eric Shaff:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Wesley C. Holmes, Esq.